Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  16.00 1.73% 940.00 900.00 980.00 940.00 935.00 935.00 13,688 11:29:30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -10.6 -16.0 - 677

Renalytix Ai Share Discussion Threads

Showing 1251 to 1274 of 1275 messages
Chat Pages: 51  50  49  48  47  46  45  44  43  42  41  40  Older
DateSubjectAuthorDiscuss
15/4/2021
09:15
What also stood out for me in yesterdays announcement was the following excerpt - "We look forward to working with Joslin and other research and pharma collaborators to build a platform to advance our understanding of underlying causal pathways of kidney disease, and bring precision medicine solutions to clinical practice." (END) Thus, it will be interesting to see if what I mention in the above post features in terms of pharma collaborators, given that the likes of AstraZeneca are attending/presenting at that conference too. Time will tell, but as indicated, Renalytix is apparently presenting study data with key findings, that include monitoring therapeutic response and impact in clinical decision making/therapy management.
wan
14/4/2021
16:41
The US appears to like today's news. From a previous post, a Renalytix excerpt - We have continued building KidneyIntelX study data with key findings to be presented at World Congress of Nephrology, American Diabetes Association and Healthcare Information and Management Systems Society in 2021. Findings include further validation in large international trial cohort, monitoring therapeutic response and impact in clinical decision making/therapy management. (END) The above Congress starts this week, so we may get another announcement/s quite soon - Congress (April 16-19) hTTps://www.theisn.org/wcn/program/
wan
14/4/2021
10:39
Yep, definitely good news to be deepening their relationship with Joslin. I also noted that the PPV for KidneyIntelX was 69% in the latest clinical research findings that were RNS'd on the 6th April, this is a very decent improvement vs 62% PPV that they stated in June 20. Granted, the two numbers aren't directly comparable, as June 2020 was for the top 16% of the population, whereas April 21's study results were for those deemed 'high risk'. However, the PPV of existing standards of care is quoted in both releases and was 41% for June 20 study vs 40% for April 21. So overall outperformance appears to have improved from 51% in June 20 to 72% in April 21, an impressive jump.
74tom
14/4/2021
10:05
Yes. Excellent news.
mr roper
14/4/2021
10:04
Another significant edge announced today in my view, in terms of widening and deepening of the moat, and potentially further expanding the utility of KidneyIntelX.
wan
12/4/2021
13:03
https://www.investing.com/news/stock-market-news/microsoft-shares-struggle-on-talk-it-may-buy-healthfocused-ai-firm-nuance-2471671 Interesting news today as Microsoft look to acquire health care ai firm.
mr roper
10/4/2021
09:33
Next week should see the fda to return to normal with the final review process. Exciting times ahead we hope. “February 2021, the FDA sent written notification to us stating that it expected the final review process would return to normal no later than April 15, 2021 and did not expect any further delays in process due to the sustained volume of EUA requests in response to the pandemic. While we will continue to decline forecasting specific timing for potential FDA clearance of KidneyIntelX, we view this notification as a positive step in the right direction“
mr roper
08/4/2021
10:29
Stifel = nomad and joint broker.
mr roper
08/4/2021
09:11
Agreed Mr Roper and Donald. The MMs are putting buyers off. (Who is Stifel?)
dontshoutatonce
08/4/2021
08:59
Agree completely, mf. 900-1000p yet you can buy at 935p. The spread just frightens investors. Buy and be 10% down a second later. Great. The company should be at least having a word with Stifel.
mr roper
08/4/2021
08:50
The spread here is ridiculous but is often sub 2% in the US. There's no reason from a trading perspective to keep the U.K. listing
donald pond
08/4/2021
07:16
Today's announcement of significant 'real-world' evidence in the performance and indication of wide adoption by primary care physicians (if KidneyIntelX was commercially available), adds to the ever-increasing and compelling weight of real-world evidence supporting KidneyIntelX, and bodes well in my view.
wan
07/4/2021
17:30
red171 - (not a tax professional). No, the Verici transaction has no tax bearing; it is certainly not a dividend. The Verici shares are assets in their own right for which you paid nothing. You pay capital gains tax as appropriate when you make a profit by selling Verici shares.
hpcg
07/4/2021
08:32
Would agree with that, wan. Thanks for posting up the Congress details. Didn’t have that in the calendar. Worth also noting the ex fda guys appointed to help specifically with approval. We are continuing to build regulatory expertise through both direct hires and retention of key contracted experts. In January 2021, we retained the services of Dr. Alberto Gutierrez, recently retired Director of the FDA's Office of In Vitro Diagnostics and Radiologic Health, and Dr. Doug Jeffery, recently retired Branch Chief and Acting Deputy Division Director in the FDA's Center for Devices and Radiological Health to support the KidneyIntelX ongoing regulatory strategy and process
mr roper
07/4/2021
08:26
Edit - Congress link added to above post
wan
07/4/2021
08:10
Fwiw, I think the fact that Renalytix has been working closely with the FDA and given Renalytix comment that "RenalytixAI expects the MCIT rule, as is or amended, will become effective within the expected 2021 FDA review and clearance period for KidneyIntelX", is very specific and I think it was made on the basis of the ongoing contact and strong working relationship with the FDA. The following from the Half Year Report is also a very important factor in providing 'additional' evidence needed to ensure the safety and effectiveness of KidneyIntelX (not to mention that revenue generation has already commenced)- Real-world Testing Experience During the quarter ended December 31, 2020, we began our clinical testing experience with KidneyIntelX within the Mount Sinai Health System. Despite COVID-19 restrictions, this real-world experience has met or exceeded targeted quality metrics and physician and patient satisfaction measures. To date, KidneyIntelX has been ordered by and test reports have been delivered to over 25 primary care and specialist physicians in the Mount Sinai network. Concurrently, we performed services for Mount Sinai to support establishing a care navigation function based on early stage DKD risk assessment, including physician and practice education, physician and patient materials, electronic order integration and care navigation deployment. We expect to start recognizing revenue from our work with Mount Sinai in the quarter ending March 31, 2021. We also anticipate expanding clinical testing deployment to additional physicians' practices in the Mount Sinai Health System through the remainder of fiscal 2021. The KidneyIntelX software platform has been designed with a number of significant features to ensure efficient clinical testing implementation and, we believe, provides an outstanding platform for future feature development. KidneyIntelX cloud computing architecture couples data control and encryption protocols and has been verified to high standards. These standards ensure secure and timely access to the order information and data necessary to execute the test in accordance with all applicable regulatory requirements. Working collaboratively with an extended team of information technology professionals, we have developed a robust data pipeline that can provide access to KidneyIntelX for all clinicians across the Mount Sinai Health System and allows the creation of a rich database (using de-identified data) for ongoing product development and shared value generation through advanced data analytics. Key features of the platform such as the patient test report incorporating health system specific care pathways are uniquely developed to be translatable to other health systems and EHR platforms. We have continued building KidneyIntelX study data with key findings to be presented at World Congress of Nephrology, American Diabetes Association and Healthcare Information and Management Systems Society in 2021. Findings include further validation in large international trial cohort, monitoring therapeutic response and impact in clinical decision making/therapy management. (END) The World Congress of Nephrology, American Diabetes Association and Healthcare Information and Management Systems Society is only 9 days away - hTTps://www.theisn.org/wcn/ and providing evidence such as that gained from the 'real world' environment in Mount Sinai, along with other key study data will addresses the crux of the main reasons for the MCIT delay i.e. a rigorous evidence-based process has already been undertaken and furthermore is still running concurrently along side the FDA review and MCIT pathway, and therefore FDA approval and MCIT coverage would not be premature, especially as it is expected that implementing and utilising KidneyIntelX testing would generate a positive return for health insurers in under 24 months and deliver a cost savings of up to $1.3 billion over five years per 100,000 patients with DKD.
wan
06/4/2021
19:25
Well in the last 12mths we’ve gone from 200p to 950p so there’s been a whole lot of leaping already. We’re current a company with a mkt cap of $900m that is just starting to generate revenue. Fda and mcit approval would catapult us on to a material growth trajectory. However, it can’t be taken for granted. On the positive side, the fda are back to normal service from next week so I’d be expecting approval in q3 if there are no hitches. Mcit should be approved in May and we should also see a couple more partnerships announced in q2. A lot coming up and I’d be thinking the next 3-4 months if things go to plan could be absolutely transformational.
mr roper
06/4/2021
19:15
Anyone interested in a tax question in connection with the distribution as a dividend in specie of VRCI shares to us RENX SHs? It seems like a RENX question about distribution rather than a VRCI question. Am I right in thinking that the distribution by RENX of VRCI shares as a dividend in specie is taxable as income, like other dividends, at the amount RENX attributes to VRCI value/number of shares in issue at record date 10 July 59,614,134? Usually a company would issue a dividend voucher to confirm details - where can those details be found? Do we have to wait for YE accounts to see the distribution information after the capital reduction entries that made it possible. If right, the VRCI shares we received without paying would then have a notional capital cost of the dividend value assessed under income tax. & any others received in placing have a CGT cost at what we actually paid out in the placing (20p?) Many thanks in advance
red171
06/4/2021
19:09
Agreed flying. The news is there for all to see and it looks as though the FDA approval is a mere formality, so why isn't it leaping? The whole great story is before us. A company this important should have a share price considerably higher, and given time, it must come. Was Easter that good for some people that they haven't woken up yet?
dontshoutatonce
06/4/2021
16:40
Considering the news in your links, the price action is maybe a little disappointing today. I guess we will fly under the radar until FDA approval
flyinggogo
05/4/2021
14:18
hxxps://investors.renalytixai.com/news-releases/news-release-details/multi-center-study-finds-kidneyintelx-72-more-effective-current Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure April 5, 2021 Download PDF Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been published in Diabetologia, the official journal of the European Association for the Study of Diabetes (EASD). Strong performance of the KidneyIntelX platform is attributed in part to its proprietary, blood-based biomarker technologies, exclusively licensed from the Joslin Diabetes Center and the Mount Sinai Health System. Notably, KidneyIntelX was observed to be highly effective at both ends of the risk spectrum. In the study, KidneyIntelX more accurately identified and segmented patients into three risk categories (low, intermediate and high) when compared to clinical models, including the current standard of care, the KDIGO risk stratification algorithm. When guideline-recommended urine albumin to creatinine ratio testing was performed, the positive predictive value (PPV) for progressive decline in kidney function was 69% for those scored as high-risk by KidneyIntelX versus the 40% identified as highest-risk by KDIGO categorization. This is a 72% improvement compared to standard of care. In addition, only 7% of those scored as low-risk by KidneyIntelX experienced progression (i.e., negative predictive value of 93%). “Diabetes is one of the leading causes of kidney failure in the United States. Appropriate treatment for kidney disease is a significant challenge in type 2 diabetes patients,” said Dr. Marina Basina, Clinical Professor, Medicine - Endocrinology, Gerontology, & Metabolism, Stanford Medicine and Medical Director of Inpatient Diabetes, Stanford Health Care. “Data from the KidneyIntelX risk assessment platform could significantly improve the care path for diabetes patients and delay the severe consequences of diabetic kidney disease. Identifying the risk for kidney disease complications in diabetic patients in the earlier stages of the disease is essential to improving kidney health and reducing health care costs.” Accurate segmentation of patient groups based on risk will yield benefits from targeted clinical care plans. High-risk patients identified earlier in the disease cycle can be prioritized to receive precision medicine and optimized care management to slow or arrest progressive kidney disease, while low-risk patients can avoid unnecessary treatments, follow-up visits and anxiety. KidneyIntelX has the potential to uniquely inform health care providers, insurance payors and population health managers about the expected rate of progression and risk of failure in early-stage kidney disease patients. KidneyIntelX is expected to support optimization of care delivery, improve patient outcomes and reduce the $120 billion annual cost of kidney disease to the United States Medicare system.1 “Given these additional clinical study findings, we are confident that KidneyIntelX will be adopted as part of the standard of care in assessing the risk of progressive kidney decline in individuals with early-stage diabetic kidney disease,” said Michael J. Donovan, MD, Ph.D., Chief Medical Officer, RenalytixAI. “These results published in Diabetologia further validate our rigorous scientific and clinical approach, which is focused on early detection and aggressive clinical intervention for those found to be at the highest risk.” The Diabetologia article entitled, “Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease,” is available at hxxps://link.springer.com/article/10.1007/s00125-021-05444
mr roper
05/4/2021
13:30
The Easter Bunny has brought some pretty good news Stateside. https://seekingalpha.com/amp/news/3679077-renalytixais-kidneyintelx-is-more-effective-in-identifying-kidney-disease-than-standard-of-care?source=feed_f&utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated&__twitter_impression=true
mr roper
30/3/2021
19:29
Bond yields
tradertrev
30/3/2021
18:07
Any news we should know about?
spittingbarrel
Chat Pages: 51  50  49  48  47  46  45  44  43  42  41  40  Older
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 05:30:44